A. J. Brahm and R. A. Hegele, Chylomicronaemia-current diagnosis and future therapies, Nat Rev Endocrinol, vol.11, pp.352-62, 2015.

C. T. Johansen and R. A. Hegele, Genetic bases of hypertriglyceridemic phenotypes, Curr Opin Lipidol, vol.22, pp.247-53, 2011.

J. De-graaf, P. Couture, and A. Sniderman, A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias, Nat Clin Pract Endocrinol Metab, vol.4, pp.608-626, 2008.

H. C. Hassing, R. P. Surendran, H. L. Mooij, E. S. Stroes, M. Nieuwdorp et al., Pathophysiology of hypertriglyceridemia, Biochim Biophys Acta, vol.1821, pp.826-858, 2012.

M. Miller, N. J. Stone, and C. Ballantyne, Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association, Circulation, vol.123, pp.2292-333, 2011.

V. Pruneta, P. Moulin, F. Labrousse, P. J. Bondon, G. Ponsin et al., Characterization of a new case of autoimmune type I hyperlipidemia: long-term remission under immunosuppressive therapy, J Clin Endocrinol Metab, vol.82, pp.791-797, 1997.

M. Moret, V. Pruneta-deloche, A. Sassolas, C. Marcais, and P. Moulin, Prevalence and function of anti-lipoprotein lipase auto-antibodies in type V hyperchylomicronemia, Atherosclerosis, vol.208, pp.324-331, 2010.

H. Yamamoto, M. Tanaka, S. Yoshiga, T. Funahashi, I. Shimomura et al., Autoimmune severe hypertriglyceridemia induced by anti-apolipoprotein C-II antibody, J Clin Endocrinol Metab, vol.99, pp.1525-1555, 2014.

A. P. Beigneux, K. Miyashita, and M. Ploug, Autoantibodies against GPIHBP1 as a Cause of Hypertriglyceridemia, N Engl J Med, vol.376, pp.1647-58, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01608620

V. Pruneta-deloche, C. Marcais, and L. Perrot, Combination of circulating antilipoprotein lipase (Anti-LPL) antibody and heterozygous S172 fsX179 mutation of LPL gene leading to chronic hyperchylomicronemia, J Clin Endocrinol Metab, vol.90, pp.3995-4003, 2005.

A. P. Ashraf, T. Beukelman, V. Pruneta-deloche, D. R. Kelly, and A. Garg, Type 1 hyperlipoproteinemia and recurrent acute pancreatitis due to lipoprotein lipase antibody in a young girl with Sjogren's syndrome, J Clin Endocrinol Metab, vol.96, pp.3302-3309, 2011.

K. L. Randall, Rituximab in autoimmune diseases, Aust Prescr, vol.39, pp.131-135, 2016.

D. Filippo, M. Marcais, C. Charriere, and S. , Post-heparin LPL activity measurement using VLDL as a substrate: a new robust method for routine assessment of plasma triglyceride lipolysis defects, PLoS One, vol.9, p.99721, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01859439

M. H. Buch, J. S. Smolen, and N. Betteridge, Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis, Ann Rheum Dis, vol.70, pp.909-929, 2011.

A. Froissart, A. Veyradier, M. Hie, Y. Benhamou, and P. Coppo, Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story, Eur J Intern Med, vol.26, pp.659-65, 2015.

S. Kihara, Y. Matsuzawa, and M. Kubo, Autoimmune hyperchylomicronemia, N Engl J Med, vol.320, pp.1255-1264, 1989.

O. Ledder, D. A. Lemberg, and A. S. Day, Thiopurine-induced pancreatitis in inflammatory bowel diseases, Expert Rev Gastroenterol Hepatol, vol.9, pp.399-403, 2015.

L. Guillevin, Rituximab for ANCA-associated vasculitides, Clin Exp Rheumatol, vol.32, pp.118-139, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01064298

R. Iorio, V. Damato, P. E. Alboini, and A. Evoli, Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis, J Neurol, vol.262, pp.1115-1124, 2015.

P. M. Kasi, H. A. Tawbi, C. V. Oddis, and H. S. Kulkarni, Clinical review: Serious adverse events associated with the use of rituximab-a critical care perspective, Crit Care, vol.16, p.231, 2012.

D. J. Blom and A. D. Marais, Severe hypertriglyceridemia in a patient with lupus, Am J Med, vol.118, pp.443-447, 2005.